A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors | Zendy

Sunil Sharma | Zendy; Joachim Beck | Zendy; Monica Mita | Zendy; Sofia Paul | Zendy; Margaret M. Woo | Zendy; Margaret Squier | Zendy; Brian Gadbaw | Zendy; H. Miles Prince | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors

Author(s) -

Sunil Sharma,

Joachim Beck,

Monica Mita,

Sofia Paul,

Margaret M. Woo,

Margaret Squier,

Brian Gadbaw,

H. Miles Prince

Publication year - 2013

Publication title -

investigational new drugs

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.254

H-Index - 87

eISSN - 1573-0646

pISSN - 0167-6997

DOI - 10.1007/s10637-013-9930-2

Subject(s) - panobinostat , medicine , tolerability , pharmacokinetics , dosing , pharmacology , pharmacodynamics , adverse effect , oncology , biochemistry , histone deacetylase , gene , histone , chemistry

Panobinostat, a pan-deacetylase inhibitor, is a promising anti-cancer agent that increases acetylation of proteins associated with growth and survival pathways of malignant cells. The primary objective of this phase I dose-escalation study was to determine the maximum tolerated dose (MTD) of intravenous (i.v.) panobinostat administered on different dosing schedules in patients with advanced solid tumors or lymphoma. Secondary objective was to characterize safety and tolerability, pharmacokinetic profiles, and activities of the i.v. formulation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research